Mitsubishi Tanabe Pharma Corporation

ALBUMOL

Chemicals used in industry, namely, recombinant human albumin to be added as a raw material for manufacturing cell culture media, diagnostic reagents, and biological medicines;

ALBUMOL

Chemicals used in industry, namely, recombinant human albumin to be added as a raw material for manufacturing cell culture media, diagnostic reagents, biological medicines, solutions for preserving cell, tissue and organ, and drug delivery agents, namely, injections, capsules, tablets, powders and implants;

ANEPHLA

Pharmaceutical preparations for the treatment of kidney disease;

ANEPHLA

Pharmaceutical preparations, namely, preparations for the treatment, control and prevention of human disorders and diseases resulting from hyperphosphatemia, hyperlipidemia, hypercholestrolemia, hyperparathyroidism, kidney dysfunction, and neurological, genetic, cardiovascular, gastrointestinal, urological, metabolic diabetic, allergy, obesity, and insulin resistance syndromes and conditions;

AVOUZAY

Pharmaceutical preparations for treatment of porphyrin metabolism disorders; pharmaceutical preparations for treatment of porphyria; pharmaceutical preparations for treatment of photodermatoses; pharmaceutical preparations for treatment of scleroderma;The wording AVOUZAY has no meaning in a foreign language.;

BINDREN

Pharmaceutical preparations, namely, preparations for the treatment, control and prevention of human disorders and diseases resulting from hyperphosphatemia, hyperlipidemia, hypercholestrolemia, hyperparathyroidism, kidney dysfunction, and neurological, genetic, cardiovascular, gastrointestinal, urological, metabolic, diabetic, allergy, obesity, and insulin resistance syndromes and conditions;

BINDREN

Pharmaceutical preparations, namely, colestilan preparations; pharmaceutical preparations for the treatment and prevention of hyperphosphatemia, chronic kidney disease, hyperlipidemia, diabetes, metabolic syndrome, hypercholesterolemia, urological diseases and disorders, cardiovascular diseases, diseases of the central and peripheral nervous system, gastrointestinal disorders, allergy, obesity, secondary hyperparathyroidism and insulin resistance syndrome;

CESORBA

Pharmaceutical preparations, namely, preparations for the treatment, control and prevention of human disorders and diseases resulting from hyperphosphatemia, hyperlipidemia, hypercholestrolemia, hyperparathyroidism, kidney dysfunction, and neurological, genetic, cardiovascular, gastrointestinal, urological, metabolic diabetic, allergy, obesity, and insulin resistance syndromes and conditions;

CLEPHEUS

Pharmaceutical preparations for the treatment of and prevention of hyperphosphatemia, chronic kidney disease, hyperlipidemia, diabetes, metabolic syndrome, hypercholesterolemia, urological diseases and disorders, cardiovascular diseases, diseases of the central and peripheral nervous system, gastrointestinal disorders, allergy, obesity, secondary hyperparathyroidism and insulin resistance syndrome;

CONQUENT

Pharmaceutical preparations for the treatment of Parkinson's disease;The wording CONQUENT has no meaning in a foreign language.;

ENLUMIS

Pharmaceutical preparations for the treatment of kidney disease;

GOPELET

Pharmaceutical preparations for the treatment of kidney diseases;GO PELLET;

HOLTORQ

Pharmaceutical preparations for the treatment of kidney diseases;

JADICUT

Pharmaceutical preparations for the treatment of central nervous system diseases; Pharmaceutical preparations for protection against free radicals; Pharmaceutical preparations for removing free radicals from the human bodies; Neuroprotective medicines; Pharmaceutical preparations for the treatment of amyotrophic lateral sclerosis (ALS);The wording JADICUT has no meaning in a foreign language.;

KEBRUVO

Pharmaceutical preparations for the treatment of kidney diseases;

KELMUTE

Pharmaceutical preparations for the treatment of kidney diseases;

LIGHTMARE

LIGHT MARE;Providing medical information of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP); providing medical information, consultancy and advisary services; medical assistance services; medical assistance services in the nature of medical information; dietary and nutritional guidance; health care services; health counselling;

LIMZORBA

Pharmaceutical preparations for the treatment of kidney disease;

LIMZORBA

Pharmaceutical preparations, namely, preparations for the treatment, control and prevention of human disorders and diseases resulting from hyperphosphatemia, hyperlipidemia, hypercholestrolemia, hyperparathyroidism, kidney dysfunction, and neurological, genetic, cardiovascular, gastrointestinal, urological, metabolic diabetic, allergy, obesity, and insulin resistance syndromes and conditions;

MITABUMIN

Chemicals used in industry, namely, recombinant human albumin to be added as a raw material for manufacturing cell culture media, diagnostic reagents, and biological medicines;

MITABUMIN

Chemicals used in industry, namely, recombinant human albumin to be added as a raw material for manufacturing cell culture media, diagnostic reagents, biological medicines, solutions for preserving cell, tissue and organ, and drug delivery agents, namely, injections, capsules, tablets, powders and implants;

MT PHARMA

Pharmaceutical preparations for protection against free radicals; pharmaceutical preparations for removing free radicals from the human bodies; pharmaceutical preparations for the treatment of amyotrophic lateral sclerosis (ALS); neuroprotective medicines; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; antiallergic medicines; antihypertensives; hypoglycemic agents; antidiabetic preparations; pharmaceutical preparations for the prevention of diabetic nephropathy; pharmaceutical preparations, namely, antiphlogistic agents; vaccine; pharmaceutical preparations for the treatment of autoimmune disease; pharmaceutical preparations for the treatment of cerebral infarction; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of erectile dysfunction;PHARMA;

NEFZUS

Pharmaceutical preparations for the treatment of kidney diseases;

NULTOX

Pharmaceutical preparations for the treatment of kidney diseases;

NURADICA

Pharmaceutical preparations for the treatment of central nervous system diseases; Pharmaceutical preparations for protection against free radicals; Pharmaceutical preparations for removing free radicals from the human bodies; Neuroprotective medicines; Pharmaceutical preparations for the treatment of amyotrophic lateral sclerosis (ALS);

ODEYVEAN

Pharmaceutical preparations for treatment of porphyrin metabolism disorders; pharmaceutical preparations for treatment of porphyria; pharmaceutical preparations for treatment of photodermatoses; pharmaceutical preparations for treatment of scleroderma;The wording ODEYVEAN has no meaning in a foreign language.;

OHANI

Pharmaceutical preparations for the treatment of Parkinson's disease;The wording OHANI has no meaning in a foreign language.;

ONERJI

The mark consists of the wording ONERJI in stylized type with the tittles on the j and i formed by single drops each having wavy horizontal lines across their centers.;Pharmaceutical preparations for the treatment of parkinson's disease;The wording ONERJI has no meaning in a foreign language.;